Advancing Immunotherapeutic Vaccine Strategies Against Pulmonary Tuberculosis

Chemotherapeutic intervention remains the primary strategy in treating and controlling tuberculosis (TB). However, a complex interplay between therapeutic and patient-related factors leads to poor treatment adherence. This in turn continues to give rise to unacceptably high rates of disease relapse...

Full description

Bibliographic Details
Main Authors:	Sam Afkhami, Anne Drumond Villela, Michael R. D’Agostino, Mangalakumari Jeyanathan, Amy Gillgrass, Zhou Xing
Format:	Article
Language:	English
Published:	Frontiers Media S.A. 2020-09-01
Series:	Frontiers in Immunology
Subjects:	tuberculosis therapeutic vaccine chemotherapy immunotherapy respiratory mucosa mycobacterial life cycle
Online Access:	https://www.frontiersin.org/article/10.3389/fimmu.2020.557809/full

id	doaj-698aadb2c0e74fd79be7168ea44c90fd
record_format	Article
spelling	doaj-698aadb2c0e74fd79be7168ea44c90fd2020-11-25T03:47:21ZengFrontiers Media S.A.Frontiers in Immunology1664-32242020-09-011110.3389/fimmu.2020.557809557809Advancing Immunotherapeutic Vaccine Strategies Against Pulmonary TuberculosisSam Afkhami0Sam Afkhami1Sam Afkhami2Anne Drumond Villela3Anne Drumond Villela4Anne Drumond Villela5Michael R. D’Agostino6Michael R. D’Agostino7Michael R. D’Agostino8Mangalakumari Jeyanathan9Mangalakumari Jeyanathan10Mangalakumari Jeyanathan11Amy Gillgrass12Amy Gillgrass13Amy Gillgrass14Zhou Xing15Zhou Xing16Zhou Xing17McMaster Immunology Research Center, McMaster University, Hamilton, ON, CanadaDepartment of Pathology and Molecular Medicine, McMaster University, Hamilton, ON, CanadaMichael G. DeGroote Institute for Infectious Disease Research, McMaster University, Hamilton, ON, CanadaMcMaster Immunology Research Center, McMaster University, Hamilton, ON, CanadaDepartment of Pathology and Molecular Medicine, McMaster University, Hamilton, ON, CanadaMichael G. DeGroote Institute for Infectious Disease Research, McMaster University, Hamilton, ON, CanadaMcMaster Immunology Research Center, McMaster University, Hamilton, ON, CanadaDepartment of Pathology and Molecular Medicine, McMaster University, Hamilton, ON, CanadaMichael G. DeGroote Institute for Infectious Disease Research, McMaster University, Hamilton, ON, CanadaMcMaster Immunology Research Center, McMaster University, Hamilton, ON, CanadaDepartment of Pathology and Molecular Medicine, McMaster University, Hamilton, ON, CanadaMichael G. DeGroote Institute for Infectious Disease Research, McMaster University, Hamilton, ON, CanadaMcMaster Immunology Research Center, McMaster University, Hamilton, ON, CanadaDepartment of Pathology and Molecular Medicine, McMaster University, Hamilton, ON, CanadaMichael G. DeGroote Institute for Infectious Disease Research, McMaster University, Hamilton, ON, CanadaMcMaster Immunology Research Center, McMaster University, Hamilton, ON, CanadaDepartment of Pathology and Molecular Medicine, McMaster University, Hamilton, ON, CanadaMichael G. DeGroote Institute for Infectious Disease Research, McMaster University, Hamilton, ON, CanadaChemotherapeutic intervention remains the primary strategy in treating and controlling tuberculosis (TB). However, a complex interplay between therapeutic and patient-related factors leads to poor treatment adherence. This in turn continues to give rise to unacceptably high rates of disease relapse and the growing emergence of drug-resistant forms of TB. As such, there is considerable interest in strategies that simultaneously improve treatment outcome and shorten chemotherapy duration. Therapeutic vaccines represent one such approach which aims to accomplish this through boosting and/or priming novel anti-TB immune responses to accelerate disease resolution, shorten treatment duration, and enhance treatment success rates. Numerous therapeutic vaccine candidates are currently undergoing pre-clinical and clinical assessment, showing varying degrees of efficacy. By dissecting the underlying mechanisms/correlates of their successes and/or shortcomings, strategies can be identified to improve existing and future vaccine candidates. This mini-review will discuss the current understanding of therapeutic TB vaccine candidates, and discuss major strategies that can be implemented in advancing their development.https://www.frontiersin.org/article/10.3389/fimmu.2020.557809/fulltuberculosistherapeutic vaccinechemotherapyimmunotherapyrespiratory mucosamycobacterial life cycle
collection	DOAJ
language	English
format	Article
sources	DOAJ
author	Sam Afkhami Sam Afkhami Sam Afkhami Anne Drumond Villela Anne Drumond Villela Anne Drumond Villela Michael R. D’Agostino Michael R. D’Agostino Michael R. D’Agostino Mangalakumari Jeyanathan Mangalakumari Jeyanathan Mangalakumari Jeyanathan Amy Gillgrass Amy Gillgrass Amy Gillgrass Zhou Xing Zhou Xing Zhou Xing
spellingShingle	Sam Afkhami Sam Afkhami Sam Afkhami Anne Drumond Villela Anne Drumond Villela Anne Drumond Villela Michael R. D’Agostino Michael R. D’Agostino Michael R. D’Agostino Mangalakumari Jeyanathan Mangalakumari Jeyanathan Mangalakumari Jeyanathan Amy Gillgrass Amy Gillgrass Amy Gillgrass Zhou Xing Zhou Xing Zhou Xing Advancing Immunotherapeutic Vaccine Strategies Against Pulmonary Tuberculosis Frontiers in Immunology tuberculosis therapeutic vaccine chemotherapy immunotherapy respiratory mucosa mycobacterial life cycle
author_facet	Sam Afkhami Sam Afkhami Sam Afkhami Anne Drumond Villela Anne Drumond Villela Anne Drumond Villela Michael R. D’Agostino Michael R. D’Agostino Michael R. D’Agostino Mangalakumari Jeyanathan Mangalakumari Jeyanathan Mangalakumari Jeyanathan Amy Gillgrass Amy Gillgrass Amy Gillgrass Zhou Xing Zhou Xing Zhou Xing
author_sort	Sam Afkhami
title	Advancing Immunotherapeutic Vaccine Strategies Against Pulmonary Tuberculosis
title_short	Advancing Immunotherapeutic Vaccine Strategies Against Pulmonary Tuberculosis
title_full	Advancing Immunotherapeutic Vaccine Strategies Against Pulmonary Tuberculosis
title_fullStr	Advancing Immunotherapeutic Vaccine Strategies Against Pulmonary Tuberculosis
title_full_unstemmed	Advancing Immunotherapeutic Vaccine Strategies Against Pulmonary Tuberculosis
title_sort	advancing immunotherapeutic vaccine strategies against pulmonary tuberculosis
publisher	Frontiers Media S.A.
series	Frontiers in Immunology
issn	1664-3224
publishDate	2020-09-01
description	Chemotherapeutic intervention remains the primary strategy in treating and controlling tuberculosis (TB). However, a complex interplay between therapeutic and patient-related factors leads to poor treatment adherence. This in turn continues to give rise to unacceptably high rates of disease relapse and the growing emergence of drug-resistant forms of TB. As such, there is considerable interest in strategies that simultaneously improve treatment outcome and shorten chemotherapy duration. Therapeutic vaccines represent one such approach which aims to accomplish this through boosting and/or priming novel anti-TB immune responses to accelerate disease resolution, shorten treatment duration, and enhance treatment success rates. Numerous therapeutic vaccine candidates are currently undergoing pre-clinical and clinical assessment, showing varying degrees of efficacy. By dissecting the underlying mechanisms/correlates of their successes and/or shortcomings, strategies can be identified to improve existing and future vaccine candidates. This mini-review will discuss the current understanding of therapeutic TB vaccine candidates, and discuss major strategies that can be implemented in advancing their development.
topic	tuberculosis therapeutic vaccine chemotherapy immunotherapy respiratory mucosa mycobacterial life cycle
url	https://www.frontiersin.org/article/10.3389/fimmu.2020.557809/full
work_keys_str_mv	AT samafkhami advancingimmunotherapeuticvaccinestrategiesagainstpulmonarytuberculosis AT samafkhami advancingimmunotherapeuticvaccinestrategiesagainstpulmonarytuberculosis AT samafkhami advancingimmunotherapeuticvaccinestrategiesagainstpulmonarytuberculosis AT annedrumondvillela advancingimmunotherapeuticvaccinestrategiesagainstpulmonarytuberculosis AT annedrumondvillela advancingimmunotherapeuticvaccinestrategiesagainstpulmonarytuberculosis AT annedrumondvillela advancingimmunotherapeuticvaccinestrategiesagainstpulmonarytuberculosis AT michaelrdagostino advancingimmunotherapeuticvaccinestrategiesagainstpulmonarytuberculosis AT michaelrdagostino advancingimmunotherapeuticvaccinestrategiesagainstpulmonarytuberculosis AT michaelrdagostino advancingimmunotherapeuticvaccinestrategiesagainstpulmonarytuberculosis AT mangalakumarijeyanathan advancingimmunotherapeuticvaccinestrategiesagainstpulmonarytuberculosis AT mangalakumarijeyanathan advancingimmunotherapeuticvaccinestrategiesagainstpulmonarytuberculosis AT mangalakumarijeyanathan advancingimmunotherapeuticvaccinestrategiesagainstpulmonarytuberculosis AT amygillgrass advancingimmunotherapeuticvaccinestrategiesagainstpulmonarytuberculosis AT amygillgrass advancingimmunotherapeuticvaccinestrategiesagainstpulmonarytuberculosis AT amygillgrass advancingimmunotherapeuticvaccinestrategiesagainstpulmonarytuberculosis AT zhouxing advancingimmunotherapeuticvaccinestrategiesagainstpulmonarytuberculosis AT zhouxing advancingimmunotherapeuticvaccinestrategiesagainstpulmonarytuberculosis AT zhouxing advancingimmunotherapeuticvaccinestrategiesagainstpulmonarytuberculosis
_version_	1724502315566628864

Advancing Immunotherapeutic Vaccine Strategies Against Pulmonary Tuberculosis

Similar Items